Hopefully some bad news for Utility Therapeutics' pivmecillinam has leaked. They are a direct competitor and up for an FDA decision in a couple weeks. The FDA could very well send them the same letter they sent ITRM, one P3 trial is not enough.
Will know by end of the month.
Of course the move could just be specs getting in ahead of the quasi binary. I doubt it is anybody who knows anything of ITRMs partner/buyout negotiations as that would move the needle harder (more volume).
News 
Market Data 
Discover 
